Search

everythinglearnresearchcommunity

for

Search:↓

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

The document concludes that better training and education are needed for proper cancer screening and criticizes the GMC's inaction as harmful to clinical ethics in the UK.

Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Sorafenib can cause a unique skin reaction.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Some cancer treatments cause different types of hair loss, but scalp cooling can help prevent it.

A man with both skin lesions and lung cancer improved quickly with chemotherapy, suggesting the skin condition might be a reaction to immune system injury.

Inhibiting the PI3K/Akt pathway may help prevent radiation-induced liver injury.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

Microneedling for hair loss may cause skin cancer.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Excessive selenium intake can cause liver damage.

Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Gefitinib therapy can cause unusual hair growth on the nose.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Cancer prevention has progressed with successful drugs and vaccines, but challenges remain in understanding genetic changes and improving strategies.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.

VHL disease can cause early paragangliomas, needing lifelong monitoring.

Some drugs can cause permanent hair loss, though it's rare.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

Older age is the main risk factor for hemorrhagic cystitis after stem cell transplants.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.